Addressing China's Rise in Biotech by Removing Barriers: Q&A with John Stanford

China's biotech sector has significantly matured, shifting from imitative practices to genuine innovation, attracting a surge of global licensing deals. The US is considering tightening foreign investment screening to address potential national security risks while facing internal challenges in supply chain, clinical trials, and technology acquisition.

This Wire brief sits within Fusion42's coverage of Biotech. Wire is Fusion42's founder-focused intelligence feed: each story is connected to the funds and startups it names — every one with a live profile on Raise or Scout — so founders can follow the capital and the momentum behind the headline rather than just the headline itself. Wire analysis is one of the live surfaces Arthur reasons over.